Mechanistic Insight into Phenolic Compounds in Mitigating Diabetic Complications Induced by Advanced Glycation End

Wajid Zaman1, Adnan Amin1

  • 1Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea.

PubMed

Insights

Phenolic compounds like quercetin and resveratrol combat diabetes complications by reducing advanced glycation end products (AGEs) and inflammation. They show potential as natural, complementary treatments for diabetes management.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Nutritional Science

Background:

  • Diabetes mellitus is a chronic metabolic disorder linked to advanced glycation end products (AGEs).
  • AGEs contribute to oxidative stress, inflammation, and vascular damage, leading to diabetic complications.
  • The receptor for AGE (RAGE) activation exacerbates tissue damage through inflammatory pathways.

Purpose of the Study:

  • To review the mechanisms by which phenolic compounds mitigate AGE-induced diabetic complications.
  • To explore the synergistic effects of phenolic compounds with antidiabetic drugs.
  • To discuss bioavailability challenges and future research directions for natural diabetes treatments.

Main Methods:

  • Review of computational, in vitro, preclinical, and clinical evidence.
  • Analysis of antioxidant and anti-inflammatory effects of phenolic compounds.
  • Examination of modulation of AGE formation and RAGE signaling.

Main Results:

  • Phenolic compounds inhibit AGE formation, reduce oxidative stress, and modulate RAGE signaling.
  • Quercetin and resveratrol demonstrate potential in preventing AGE accumulation and improving insulin sensitivity.
  • Evidence supports the role of these compounds in managing diabetic nephropathy and enhancing glucose homeostasis.

Conclusions:

  • Phenolic compounds are promising complementary agents for diabetes therapy.
  • Natural compounds offer potential for developing more effective diabetes treatments.
  • Further research into synergistic effects and bioavailability is warranted.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
521
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K